At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
NMRA-335140 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating NMRA-335140 and Placebo for Major Depressive Disorder. Completed, enrolled 204 participants across 38 sites.
Detailed Summary
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedJan 2020
Primary CompletionApr 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJan 9, 2020
Enrollment StartJan 3, 2020
Primary CompletionApr 8, 2022
Study CompletionJun 23, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.5 years ago
Interventions
NMRA-335140drug
Active Drug
Placebodrug
Placebo